Nevirapine versus efavirenz-based antiretroviral therapy regimens in antiretroviral-naive patients with HIV and tuberculosis infections in India: a pilot study

Sanjeev Sinha, Puroshottam Raghunandan, Rahul Chandrashekhar, Surendra K Sharma, Sanjiv Kumar, Sahajal Dhooria, Meera Ekka, Thirumurthy Velpandian, Sanjay Ranjan, Hafeez Ahmad, Jyotish Chandra Samantaray, Srinivasaraghavan Venkatesh, Bharat Bhushan Rewari, Nawaid Hussain Khan, Ravindra Mohan Pandey, Sanjeev Sinha, Puroshottam Raghunandan, Rahul Chandrashekhar, Surendra K Sharma, Sanjiv Kumar, Sahajal Dhooria, Meera Ekka, Thirumurthy Velpandian, Sanjay Ranjan, Hafeez Ahmad, Jyotish Chandra Samantaray, Srinivasaraghavan Venkatesh, Bharat Bhushan Rewari, Nawaid Hussain Khan, Ravindra Mohan Pandey

Abstract

Background: Administration of rifampicin along with nevirapine reduces the plasma concentration of nevirapine in human immunodeficiency virus positive individuals with concomitant tuberculosis (HIV-TB patients). Nevirapine is a much cheaper drug than its alternative efavirenz, and might be beneficial in resource constrained settings.

Methods: A randomised open label trial was conducted at All India Institute of Medical Sciences, New Delhi, India. During the regimen of an antiretroviral therapy (ART), naive HIV-TB patients were randomly assigned to receive either nevirapine or efavirenz based ART with concomitant rifampicin based anti-tubercular therapy (ATT). Participants were followed for 24 months after starting ART. The end points were virological, immunological and clinical responses, and progression of HIV disease marked by failure of ART.

Results: Of the 135 HIV-TB patients, who were receiving rifampicin based ATT, 68 were selected randomly to receive efavirenz based ART and 67 to receive nevirapine based ART. The virological failure rates in the overall population, and the nevirapine and efavirenz groups were 14.1% (19/135); 14.9% (10/67) and 13.2% (9/68), respectively (p =0.94). No significant difference was found between the groups in the rate of clinical, immunological or virological failures. The overall mortality was 17% with no significant difference between the two groups. Except for the lead in period on day 14, the mean nevirapine concentration remained above 3 mg/L. No association was found between plasma levels of nevirapine and incidence of unfavourable outcomes in this group.

Conclusions: Outcome of ART in HIV-TB patients on rifampicin based ATT showed no significant difference, irrespective of whether efavirenz or nevirapine was used. Therefore, nevirapine based ART could be an alternative in the resource limited settings in patients with HIV and tuberculosis co-infection.

Trial registration: NCT No. 01805258.

Trial registration: ClinicalTrials.gov NCT01805258.

Figures

Figure 1
Figure 1
Screening, enrolment and follow-up of study participants.
Figure 2
Figure 2
CD4 cell count at different time points in nevirapine and efavirenz groups.NVP nevirapine, EFV efavirenz.
Figure 3
Figure 3
Viral load count at different time points in log scale in nevirapine and efavirenz group.NVP nevirapine, EFV efavirenz.
Figure 4
Figure 4
Kaplan Meier survival curve with cumulative probability of death or ART failure by 24 months.NVP nevirapine, EFV efavirenz.
Figure 5
Figure 5
Plasma Nevirapine concentrations at different time points in nevirapine group.

References

    1. Joint United Nations Programme on HIV/AIDS. Global report: UNAIDS report on the global AIDS epidemic. Geneva; 2010. Available: .
    1. World Health Organization. Global tuberculosis report 2012. Geneva; 2012. Available:
    1. National AIDS Control Organisation India, Department of AIDS Control, Ministry of Health & Family Welfare. National AIDS control organization: annual report 2011–12. New Delhi; 2013. Available: .
    1. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. Geneva; 2010. Available: .
    1. National AIDS Control Organisation, Ministry of Health & Family Welfare, India. Antiretroviral therapy guidelines for HIV-infected adults and adolescents including post-exposure prophylaxis. New Delhi; 2007. Available:
    1. Niemi M, Backman JT, Fromm MF, Neuvonen PJ, Kivistö KT. Pharmacokinetic interactions with rifampicin: clinical relevance. Clin Pharmacokinet. 2003;42:819–850. doi: 10.2165/00003088-200342090-00003.
    1. Cohen K, Cutsem van G, Boulle A, McIlleron H, Goemaere E, Smith PJ, Maartens G. Effect of rifampicin-based antitubercular therapy on nevirapine plasma concentrations in south African adults with HIV-associated tuberculosis. J Antimicrob Chemother. 2008;61:389–393.
    1. Van Oosterhout JJG, Kumwenda JJ, Beadsworth M, Mateyu G, Longwe T, Burger DM, Zijlstra EE. Nevirapine-based antiretroviral therapy started early in the course of tuberculosis treatment in adult Malawians. Antivir Ther. 2007;12:515–521.
    1. Manosuthi W, Mankatitham W, Lueangniyomkul A, Chimsuntorn S, Sungkanuparph S. Standard-dose efavirenz vs. Standard-dose nevirapine in antiretroviral regimens among HIV-1 and tuberculosis co-infected patients who received rifampicin. HIV Med. 2008;9:294–299. doi: 10.1111/j.1468-1293.2008.00563.x.
    1. Sinha S, Dhooria S, Kumar S, Shah N, Velpandian T, Ravi A, Kumar N, Ahmad H, Bhargwa A, Chug K, Bumma N, Chandrashekhar R, Ekka M, Sreenivas V, Sharma SK, Samantaray J, Mitsuyasu R. The antiretroviral efficacy of highly active antiretroviral therapy and plasma nevirapine concentrations in HIV-TB co-infected Indian patients receiving rifampicin based antituberculosis treatment. AIDS Res Ther. 2011;8:41. doi: 10.1186/1742-6405-8-41.
    1. Van Leth F, Phanuphak P, Ruxrungtham K, Baraldi E, Miller S, Gazzard B, Cahn P, Lalloo UG, van der Westhuizen IP, Malan DR, Johnson MA, Santos BR, Mulcahy F, Wood R, Levi GC, Reboredo G, Squires K, Cassetti I, Petit D, Raffi F, Katlama C, Murphy RL, Horban A, Dam JP, Hassink E, van Leeuwen R, Robinson P, Wit FW, Lange JMA. 2NN Study team. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. Lancet. 2004;363:1253–1263. doi: 10.1016/S0140-6736(04)15997-7.
    1. Mbuagbaw LC, Irlam JH, Spaulding A, Rutherford GW, Siegfried N. Efavirenz or nevirapine in three-drug combination therapy with two nucleoside-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals. Cochrane Database Syst Rev. 2010. p. CD004246. doi:10.1002/ 14651858.CD004246.pub3.
    1. World Health Organization, Stop TB Initiative. The treatment of tuberculosis guidelines. Geneva; 2010. Available: .
    1. Boulle A, Van Cutsem G, Cohen K, Hilderbrand K, Mathee S, Abrahams M, Goemaere E, Coetzee D, Maartens G. Outcomes of nevirapine- and efavirenz-based antiretroviral therapy when coadministered with rifampicin-based antitubercular therapy. JAMA. 2008;300:530–539. doi: 10.1001/jama.300.5.530.
    1. Varma JK, Nateniyom S, Akksilp S, Mankatittham W, Sirinak C, Sattayawuthipong W, Burapat C, Kittikraisak W, Monkongdee P, Cain KP, Wells CD, Tappero JW. HIV care and treatment factors associated with improved survival during TB treatment in Thailand: an observational study. BMC Infect Dis. 2009;9:42. doi: 10.1186/1471-2334-9-42.
    1. Manosuthi W, Ruxrungtham K, Likanonsakul S, Prasithsirikul W, Inthong Y, Phoorisri T, Sungkanuparph S. Nevirapine levels after discontinuation of rifampicin therapy and 60-week efficacy of nevirapine-based antiretroviral therapy in HIV-infected patients with tuberculosis. Clin Infect Dis. 2007;44:141–144. doi: 10.1086/510078.
    1. Shipton LK, Wester CW, Stock S, Ndwapi N, Gaolathe T, Thior I, Avalos A, Moffat HJ, Mboya JJ, Widenfelt E, Essex M, Hughes MD, Shapiro RL. Safety and efficacy of nevirapine- and efavirenz-based antiretroviral treatment in adults treated for TB-HIV co-infection in Botswana. Int J Tuberc Lung Dis. 2009;13:360–366.
    1. Swaminathan S, Padmapriyadarsini C, Venkatesan P, Narendran G, Ramesh Kumar S, Iliayas S, Menon PA, Selvaraju S, Pooranagangadevi NP, Bhavani PK, Ponnuraja C, Dilip M, Ramachandran R. Efficacy and safety of once-daily nevirapine- or efavirenz-based antiretroviral therapy in HIV-associated tuberculosis: a randomized clinical trial. Clin Infect Dis. 2011;53:716–724. doi: 10.1093/cid/cir447.
    1. Manosuthi W, Sungkanuparph S, Tantanathip P, Lueangniyomkul A, Mankatitham W, Prasithsirskul W, Burapatarawong S, Thongyen S, Likanonsakul S, Thawornwa U, Prommool V, Ruxrungtham K. the NR Study Team. A randomized trial comparing plasma drug concentrations and efficacies between 2 Non-nucleoside reverse-transcriptase inhibitor-based regimens in HIV-infected patients receiving rifampicin: the N 2 R study. Clin Infect Dis. 2009;48:1752–1759. doi: 10.1086/599114.
    1. Lamorde M, Byakika-Kibwika P, Okaba-Kayom V, Ryan M, Coakley P, Boffito M, Namakula R, Kalemeera F, Colebunders R, Back D, Khoo S, Merry C. Nevirapine pharmacokinetics when initiated at 200 mg or 400 mg daily in HIV-1 and tuberculosis co-infected Ugandan adults on rifampicin. J Antimicrob Chemother. 2011;66:180–183. doi: 10.1093/jac/dkq411.
    1. El-Sadr WM, Perlman DC, Denning E, Matts JP, Cohn DL. A review of efficacy studies of 6-month short-course therapy for tuberculosis among patients infected with human immunodeficiency virus: differences in study outcomes. Clin Infect Dis. 2001;32:623–632. doi: 10.1086/318706.
    1. Khan FA, Minion J, Pai M, Royce S, Burman W, Harries AD, Menzies D. Treatment of active tuberculosis in HIV-coinfected patients: a systematic review and meta-analysis. Clin Infect Dis. 2010;50:1288–1299. doi: 10.1086/651686.
    1. Moses M, Zachariah R, Tayler-Smith K, Misinde D, Foncha C, Manzi M, Bauerfeind A, Mwagomba B, Kwanjana J, Harries AD. Outcomes and safety of concomitant nevirapine and rifampicin treatment under programme conditions in Malawi. Int J Tuberc Lung Dis. 2010;14:197–202.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel